Key result
Recombinant human thrombopoietin 300 U/kg/day ranked highest for reducing 28-day mortality, while 15000 U/day ranked highest for shortening ICU stay.
Why the study?
Sepsis remains a common critical illness, prompting an evaluation of the comparative therapeutic value of recombinant human thrombopoietin for sepsis-related thrombocytopenia.
Does recombinant human thrombopoietin (rhTPO) improve platelet levels, reduce transfusion requirements, and decrease mortality in sepsis patients with thrombocytopenia?
Meta-Analysis (n=963)
Does recombinant human thrombopoietin (rhTPO) improve platelet levels, reduce transfusion requirements, and decrease mortality in sepsis patients with thrombocytopenia?
Answers are grounded in this paper and cite their sources.
In patients with sepsis-related thrombocytopenia, rhTPO 300 U/kg/day may be the optimal dose to reduce 28-day mortality and transfusion requirements, while 15000 U/day may best shorten ICU stay and increase early platelet levels.
Previous studies suggest that sepsis remains a common critical illness with a global incidence of 31.5 million. The aim of this study was to evaluate the comparative therapeutic value of recombinant human thrombopoietin (rhTPO) in treating sepsis patients with thrombocytopenia. We conducted a comprehensive electronic search of PubMed, EMBASE, the Cochrane Library, and CNKI from its inception through December 31, 2021. Thirteen randomized controlled trials (RCTs) involving 963 patients were included. Network meta‐analyses showed that rhTPO 300 U/kg/day and rhTPO 15000 U/day significantly increased the platelet (PLT) levels on the 7th day and decreased the requirement of transfusion of red blood cells (RBCs), plasma, and PLT compared with IVIG and NAT. SUCRA showed that rhTPO 300 U/kg/day ranked first in terms of 28‐day mortality (85.5%) and transfusion, including RBC (88.7%), plasma (89.6%), and PLT (95.2%), while rhTPO 15000 U/day ranked first for the length of the intensive care unit (ICU) stay (95.9%) and PLT level at day 7 (91.6%). rhTPO 300 U/kg/day may be the optimal dose to reduce 28‐day mortality and transfusion requirements. However, rhTPO 15000 U/day may be the optimal dose for shortening the ICU stay and increasing the PLT level on the 7th day. However, additional studies to further validate our findings are needed.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) conducted a meta-analysis in sepsis-related thrombocytopenia (n=963). recombinant human thrombopoietin (rhTPO) vs. IVIG and NAT was evaluated on platelet levels on the 7th day, requirement of transfusion, 28-day mortality, and length of ICU stay. Recombinant human thrombopoietin 300 U/kg/day ranked highest for reducing 28-day mortality, while 15000 U/day ranked highest for shortening ICU stay.
Synapse has enriched 10 related papers. Consider them for comparative context: